Pfizer of the United States and Bio-Tech of Germany first released preliminary results of the third and final phase of their human coronary vaccine trial on November 9, calling it more than 90% effective in protecting against the disease.
It has now become the world's first vaccine to have a final phase trial completed and final results released, and the companies will now submit an application to the US Food and Drug Administration for emergency use approval.
The final results show that the vaccine is 95% effective in preventing the disease.
Both companies say they have enough data to meet US drug regulator requirements and will submit an emergency use clearance request in the next few days.
Last week, the two companies said in preliminary results of the third phase that its utility rate was more than 90%, which scientists called higher than expected.
Another US company that is using a genetic technology-based vaccine, such as the Pfizer vaccine, said in its preliminary results this week that its vaccine is 94.5% effective in protecting against disease.
Preliminary results of Russia's vaccine were released last week, calling it 92% peacock for disease protection.
Pfizer chairman and chief executive Albert Borla said of the final findings, "The findings are a significant milestone in an eight-month journey that has helped bring forward a vaccine capable of preventing a deadly epidemic."
"We will continue this pace and all the data will be shared with regulators around the world," he said.
American and German companies have released the final results of the final phase of the world's first experimental corona vaccine, and say they expect to produce 50 million doses this year.
Keep in mind that if the vaccine is used in two doses, 50 million doses will be for 25 million people, while next year these companies are hoping to produce 1.3 billion doses.
The World Health Organization and other regulators have declared corona vaccines to be at least 50% effective, but recent results from vaccines have exceeded expectations.
Pfizer said the vaccine's efficacy was consistent across different ages, genders and minority groups.
Among people over the age of 65 who are most at risk for the disease, the vaccine coverage is 94 percent.
The trial involved 43,000 people and diagnosed corona in 170, of which 162 belonged to the placebo group.
The research team said that in the trial, the severity of the disease was serious in 10 cases, of which 9 were in the placebo group and one in the vaccine group.
He said the study did not show any significant safety concerns, with 8,000 people experiencing side effects, but fatigue and headaches were the most serious.
The US government has already bought 100 million doses of the vaccine for 95 1.95 billion, and plans to buy another 500 million doses.
As far as developing countries like Pakistan are concerned, this vaccine is not suitable for them due to various problems.
Pfizer's experimental vaccine for early prevention of Code 19 epidemic in most Asian countries, including Pakistan, and developing nations, due to hot weather, populations in remote areas, lack of freezers providing extreme cooling and limited availability of vaccines. Can't depend on
The vaccine will need to be stored at minus 70 degrees Celsius or less.
According to the NPR report, Pfizer will produce a limited number of doses of the vaccine by 2021 (1.3 billion), and one person will be given 2 doses over a 21-day period.
That means 1.3 billion doses will only be used by 650 million people, while 80 percent of the company's supply has already been purchased by the United States, the United Kingdom, the European Union, Canada and Japan.
Simply put, it will be very difficult for other countries, especially poor ones, to get vaccines.
Professor Ata-ur-Rehman, head of the Science and Technology Task Force, told VOA that Pfizer's Corona vaccine is not suitable for developing countries due to its cold storage needs.
He said it would be premature for Pakistan and other developing countries to be happy with Pfizer's announcement.
"Cold storage infrastructure and chains to transport the vaccine from the airport to cities and countries are not available in developing countries,"
He said that 2 doses of this vaccine would be required at intervals of 21 days and during this period it would be most difficult to keep it safe at extremely low temperatures.
Similar sentiments were expressed by Dr Faisal Sultan, Special Assistant to the Prime Minister for Health.
"It will be a big challenge for us to manage the cold chain for the vaccine. If our cold chain system is not able to operate at this temperature, then we have to make new arrangements for its supply across the country," he told Dawn.
